Evidence map›Paper›PMID 35471681›Full record

ReviewEJNMMI radiopharmacy and chemistry2022

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Emerson Bernardes, Peter Caravan, R Michael van Dam, Winnie Deuther-Conrad, Beverley Ellis, Shozo Furumoto, Benjamin Guillet, Ya-Yao Huang, Hongmei Jia, Peter Laverman and 13 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Emerson BernardesIPEN, São Paulo, Brazil.
Peter CaravanMassuchusetts General Hospital, Harvard University, Cambridge, USA.
R Michael van DamUniversity of California, Los Angeles, Los Angeles, USA.
Winnie Deuther-ConradHelmholtz-Zentrum Dresden-Rossendorf (HZDR), Leipzig, Germany. w.deuther-conrad@hzdr.de.ORCID http://orcid.org/0000-0003-3168-3062
Beverley EllisManchester University NHS Foundation Trust, Manchester, UK.
Shozo FurumotoCYRIC, Tohoku University, Sendai, Japan.
Benjamin GuilletCERIMED, C2VN, Aix-Marseille Univ, Marseille, France.
Ya-Yao HuangNational Taiwan University College of Medicine, Taipei, Taiwan.
Hongmei JiaBeijing Normal University, Beijing, China.
Peter LavermanUniversity of Alberta, Edmonton, Canada.
Zijing LiXiamen University, Xiamen, China.
Zhaofei LiuPeking University, Beijing, China.
Filippo LodiS. Orsola-Malpighi Hospital, Bologna, Italy.
Yubin MiaoUniversity of Colorado, Denver, USA.
Lars PerkRadboud University Medical Center, Nijmegen, The Netherlands.
Ralf SchirrmacherUniversity of Alberta, Edmonton, Canada.
Johnny VercoullieUniversity of Tours, Tours, France.
Hua YangTRIUMF, Vancouver, Canada.
Min YangJiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, People's Republic of China.
Xing YangPeking University First Hospital, Beijing, China.
Junbo ZhangBeijing Normal University, Beijing, China.
Ming-Rong ZhangNIRS, Chiba, Japan.
Hua ZhuPeking University Cancer Hospital, Beijing, China.

Funding

PET Imaging of ThrombusR01HL109448 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D, SOSNOVIK, DAVID E · 2011 to 2025
$9.6M
PET-MR Imaging of pulmonary fibrosisR01HL153606 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D, CATANA, CIPRIAN · 2021 to 2025
$4.1M
Novel Receptor-Targeting Peptides for Melanoma TherapyR01CA225837 · NCI · UNIVERSITY OF COLORADO DENVER · PI MIAO, YUBIN · 2018 to 2022
$1.9M
Optimization of PET probe for imaging lung fibrogenesisR33HL154125 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2020 to 2021
$1.2M
NCI NIH HHS R01 CA225837NHLBI NIH HHS R01 HL109448NHLBI NIH HHS R01 HL153606NHLBI NIH HHS R33 HL154125
6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

resultsThis commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included.

conclusionTrends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Indexed as

HighlightsRadiochemistryRadiopharmacyReview

Identifiers

PMID35471681
PMCPMC9043146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.